1. KD. Tripathi. Antiepileptic drugs. Essentials of medical pharmacology. Seventh edition. 2013. Page – 415-416.
2. Johnathan M. Meyer. Pharmacotherapy of Psychosis and Mania. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 12th Edition. New York McGraw Hill Medical 2011. Page – 444-451.
3. James O. McNamara. Pharmacotherapy of the Epilepsies. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 12th Edition. New York McGraw Hill Medical 2011. Page – 594-596.
4. Gerald G. Briggs and Roger K. Freeman. C. A reference guide to fetal and neonatal risk: Drugs in Pregnancy and Lactation. Tenth Edition. 2015. Page – 581-592.
5. Lundbeck LLC. A Study of the Pharmacokinetics (PK) and Safety of IV Carbamazepine Relative to Oral Carbamazepine in Adults with Epilepsy. NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on April 2010] [Accessed 26th November 2020] https://clinicaltrials.gov/ct2/show/NCT01079351
6. Zahra Tolou-Ghamari, Mohammad Zare, Jafar Mehvari Habibabadi, and Mohammad Reza Najafi. A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012. NCBI; PMC US National Library of Medicine, National Institute of Health. March 2013. [Accessed 26th November 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743329/
7. Novartis Pharmaceuticals UK Limited and Novartis Farma S.p.A. Electronic Medicines Compendium (EMC); [Revised on October 2020] [Accessed 26th November 2020] https://www.medicines.org.uk/emc/files/pil.1040.pdf
8. Novartis Pharmaceuticals Corporation. U.S. Food & Drug Administration. [Revised on February 2009] [Accessed 26th November 2020] https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016608s101,018281s048lbl.pdf